Adjunct mirtazapine for negative symptoms of schizophrenia

Pharmacotherapy

Volumn 31, Issue 10, 2011, Pages 1017-1030

  Phan, Stephanie V ^a   Kreys, Tiffany Jade M ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF THE INCARNATE WORD   (United States)

Author keywords

Add on; Adjunct; Antidepressant; Antipsychotic; Augmentation; Mirtazapine; Negative symptoms; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 3 RECEPTOR; TRIFLUOPERAZINE;

ADD ON THERAPY; ADJUVANT THERAPY; AGGRESSION; AGITATION; ANXIETY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEART RATE; HUMAN; INCREASED APPETITE; INSOMNIA; LOW DRUG DOSE; NAUSEA; NEGATIVE SYNDROME; NERVE STIMULATION; NEUROPATHOLOGY; OUTCOME ASSESSMENT; PARKINSONISM; POSITIVE SYNDROME; PROTEIN FUNCTION; PSYCHOLOGICAL RATING SCALE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TOTAL QUALITY MANAGEMENT; TREATMENT DURATION; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MIANSERIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 80053330201     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.10.1017     Document Type: Review

References (75)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50:85-94. (Pubitemid 23059313)
2. U.S. Census Bureau. Population estimates by demographic characteristics. Table 2: annual estimates of the population by selected age groups and sex for the United States: April 1, 2000 to July 1, 2004 (NC-EST2004-02). Release date: June 9, 2005. Available from http://www.census.gov/popest/national/asrh/. Accessed October 1, 2010.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revised. Washington, DC: American Psychiatric Association; 2000.
4. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. Washington, DC: American Psychiatric Association; 2004.
5. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32:214-19.
6. Buchanan RW, Gold JM. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharm 1996;11(suppl 2):3-11. (Pubitemid 26194495)
7. Buchanan RW, Carpenter WT. Domains of psychopathology and approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 2006;182:193-204.
8. Pogue-Geile MF, Harrow M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr Bull 1985;11:427-39. (Pubitemid 15036186)
9. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991;48:239-46.
10. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991;48:978-86.
11. Ribeiro SCM, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF. Clinical predictors of 1-year outcome in schizophrenia. Psychopathology 1992;25:331-4. (Pubitemid 23082165)
12. Addington J, Addington D. Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia. J Psychiatry Neurosci 1993;18:18-23.
13. Lysaker P, Bell M. Negative symptoms and vocational impairment in schizophrenia: repeated measurements of work performance over six months. Acta Psychiatr Scand 1995;91: 205-8.
14. Jonasson SAT, Jonasson H. Outcome in untreated schizophrenia: a search for symptoms and traits with prognostic meaning in patients admitted to the mental hospital in the preneuroleptic era. Acta Psychiatr Scand 1992;85:313-20.
15. Mayerhoff DL, Loebel AD, Alvir JMJ, et al. The deficit state in first episode schizophrenia. Am J Psychiatry 1994;151: 1417-22. (Pubitemid 24301684)
16. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148:1474-86.
17. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
18. Volonté M, Monferini E, Cerutti M, Fodritto F, Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 1997;69:182-90. (Pubitemid 27274171)
19. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999;288:774-81. (Pubitemid 29119694)
20. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn S. 5-HT1Areceptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000;48:229-37. (Pubitemid 30618995)
21. 3 dopamine receptor occupancy by quetiapine in vivo: [123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 2000;177:408-15.
22. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72. (Pubitemid 37464960)
23. Ichikawa J, Meltzer HY. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 1999;291:1227-32.
24. O'Grada C, Dinan T. Executive function in schizophrenia: what impact do antipsychotics have? Hum Psychopharmacol Clin Exp 2007;22:397-406.
25. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38.
26. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. (Pubitemid 41345943)
27. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87. (Pubitemid 44498387)
28. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68. (Pubitemid 29023554)
29. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
30. Davis JM, Chen N, Click ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64. (Pubitemid 36682312)
31. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
32. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophren Bull 2006;32:234-7.
33. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandro-sterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003;60:133-41. (Pubitemid 36173119)
34. Jungerman T, Rabinowit D, Klein E. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double blind, controlled study. J Clin Psychopharmacol 1999;19:522-5.
35. Gupta S, Droney T, Kyser A, Keller P. Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry 1999;40:148-50. (Pubitemid 29108626)
36. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res 2005;80:85-97. (Pubitemid 41587466)
37. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010;197:174-9.
38. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005;6:132-91.
39. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5-40. (Pubitemid 43878525)
40. 2-selective adrenoreceptor antagonist Org 3770 (mirtazapine Remeron) enhances noradrenergic and serotonergic neurotransmission. Hum Psychopharmacol 1995;10:S107-18.
41. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psych 1996;57(suppl 4):19-25. (Pubitemid 26177340)
42. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10-21. (Pubitemid 27057115)
43. Zoccali R, Muscatello MR, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004;19:71-6. (Pubitemid 38324586)
44. Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and noradrenergic, but not serotonergic, transmission by blockade of alpha-2-adrenergic and serotonin 2C receptors: a comparison with citalopram. Eur J Neurosci 2000;12:1079-95. (Pubitemid 30168787)
45. Carboni E, Tanda GL, Frau R, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990;55:1067-70.
46. DeVoto P, Flore G, Pira L, Longu G, Gessa GL. Mirtazapine-induced cortical release of dopamine and noradrenaline from noradrenergic neurons in the medical prefrontal and occipital cortex. Eur J Pharmacol 2004;487:105-11. (Pubitemid 38368986)
47. Brunello N, Blier P, Judd LL, et al. Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int Clin Psychopharmacol 2003;18:191-202. (Pubitemid 36871870)
48. Dell'Osso B, Palazzo MC, Oldani L, Altamura AC. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects [published online ahead of print December 14, 2010]. CNS Neurosci Ther. Available from http://dx.doi.org/10.1111/j.1755-5949.2010.00217.x.
49. Kay SR, Fiszbein A, Opier LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)
50. Andreasan N. The scale for the assessment of negative symptoms (SANS). Iowa City, IA: University of Iowa, Department of Psychiatry, 1981.
51. Stenberg JH, Terevnikov V, Joffe M, et al. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:433-41.
52. Stenberg JH, Terevnikov V, Joffe M, et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35: 1080-6.
53. Loonen AJM, Doorschot CH, Oostelbos MCJM, Sitsen JMA. Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. Eur Neuropsychopharmacol 1999;10:51-7.
54. Zoccali R, Muscatello MR, La Torre D, et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 2003;48:411-14. (Pubitemid 36945340)
55. N.V. Organon, Schering-Plough Corporation. Remeron (mirtazapine) package insert. Oss, Netherlands; May 2010.
56. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
57. Lachar D, Bailley SE, Rhoades HM, Varner RV. Use of BPRS-A percent change scores to identify clinical improvement: accuracy of treatment response classification in acute psychiatric inpatients. Psychiatry Res 1999;89:259-68. (Pubitemid 30053008)
58. Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001;16:87-92. (Pubitemid 32171833)
59. Delle Chiaie R, Salviati M, Fiorentini S, Biondi M. Add-on mirtazapine enhances effects of cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol 2007;15:563-8. (Pubitemid 351163131)
60. Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. Add-on mirtazapine enhances antipsychotic effect of first-generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophrenia Res 2009;108:245-51.
61. Terevnikov V, Stenberg JH, Joffe M, et al. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial. Hum Psychopharmacol 2010;25:431-8.
62. Berk M, Gama CS, Sundram S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomized, placebo-controlled clinical trial. Hum Psychopharmacol 2009;24:233-8.
63. Abbasi SH, Behpournia H, Ghoreshi A, et al. The effect of mirtazapine add-on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophrenia Res 2010;116:101-6.
64. Cho SJ, Yook K, Kim B, et al. Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:208-11.
65. Fawcett J, Barkin R. Review of the results from clinical studies on the efficacy, safety and tolerability or mirtazapine for the treatment of patients with major depression. J Affect Disorders 1998;51:267-85. (Pubitemid 29202175)
66. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006;67:421-4.
67. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72.
68. Correll CU, Kane JM, Manu P. Obesity and coronary risk in patients treated with second-generation antipsychotics [published online ahead of print December 12, 2010]. Eur Arch Psychiatry Clin Neurosci. Available from http://dx.doi.org/10.1007/s00406-010-0177-z.
69. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68:2269-92.
70. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull 2006;32:225-30.
71. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006;32:238-45.
72. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
73. Laughren T, Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr Bull 2006;32:220-2.
74. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-51. (Pubitemid 20228720)
75. Capital Medical University. Evaluation of mirtazapine and folic acid for schizophrenia: (RECOVERY2). Clinicaltrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01263080?term= mirtazapine+ AND+schizophrenia&rank=1. Accessed April 30, 2011.